基于生物标志物的策略用于重症患者早期停用经验性抗真菌治疗:一项随机对照试验
本研究为前瞻性随机对照单中心非盲研究,纳入110例混合ICU中接受经验性抗真菌治疗的患者,随机分为生物标志物策略组(第0天和第4天检测(1,3)-β-D-葡聚糖、甘露聚糖和抗甘露聚糖抗体,按算法决定是否早期停用)和常规策略组(按国际指南推荐14天疗程)。主要终点为存活者中早期停用(严格早于第7天)经验性抗真菌治疗的比例,生物标志物策略组为54%(29/54),常规策略组为2%(1/55),p<0.001,OR 62.6(95%CI 8.1-486)。抗真菌治疗总时长生物标志物策略组中位6天(IQR 4-13),常规策略组中位13天(IQR 12-14),p<0.0001。两组在后续确诊侵袭性念珠菌感染比例、无机械通气天数、ICU住院时长、费用和ICU死亡率方面无显著差异。作者结论认为该策略可提高早期停用比例且对结局无负面影响,但需进一步研究确认安全性。
要点
- 在疑似侵袭性念珠菌感染的重症患者中,基于(1,3)-β-D-葡聚糖、甘露聚糖和抗甘露聚糖抗体的策略使54%(29/54)的存活者早期停用经验性抗真菌治疗,常规策略组仅2%(1/55),p<0.001。
- 生物标志物策略组抗真菌治疗总时长中位6天(IQR 4-13),显著短于常规策略组的13天(IQR 12-14),p<0.0001。
- 两组后续确诊侵袭性念珠菌感染比例、无机械通气天数、ICU住院时长、费用和ICU死亡率无显著差异。
- 作者认为早期停用经验性抗真菌治疗对结局无负面影响,但进一步研究仍需确认该策略的安全性。
适用人群与场景
- 混合ICU中接受经验性抗真菌治疗、疑似侵袭性念珠菌感染的重症患者。
处置流程与药物剂量
- 生物标志物策略组:在第0天和第4天检测(1,3)-β-D-葡聚糖、甘露聚糖和抗甘露聚糖抗体血清学,依据基于上述标志物结果的算法决定是否推荐早期停用经验性抗真菌治疗。
- 常规策略组:依据国际指南推荐,经验性抗真菌治疗疗程为14天。
研究设计与关键结果
- 研究类型:前瞻性随机对照单中心非盲研究,纳入110例混合ICU患者,1例撤回知情同意后分析109例(生物标志物策略组54例,常规策略组55例)。
- 主要终点:存活者中早期停用(严格早于第7天)经验性抗真菌治疗的比例,生物标志物策略组54%(29/54) vs 常规策略组2%(1/55),p<0.001,OR 62.6(95%CI 8.1-486)。
- 抗真菌治疗总时长:生物标志物策略组中位6天(IQR 4-13) vs 常规策略组中位13天(IQR 12-14),p<0.0001。
- 两组后续确诊侵袭性念珠菌感染比例、无机械通气天数、ICU住院时长、费用和ICU死亡率无显著差异。
证据类型、等级与局限
- 证据类型:前瞻性随机对照单中心非盲研究。
- 局限:作者指出需进一步研究确认该策略的安全性。
对床旁实践的改变
- 对于疑似侵袭性念珠菌感染而启动经验性抗真菌治疗的重症患者,可考虑在第0天和第4天检测(1,3)-β-D-葡聚糖、甘露聚糖和抗甘露聚糖抗体,并依据基于上述标志物的算法决定是否早期停用经验性抗真菌治疗,以缩短治疗时长。
- 作者认为早期停用经验性抗真菌治疗对结局无负面影响,但进一步研究仍需确认该策略的安全性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: The aim of this study was to determine the impact of a biomarker-based strategy on early discontinuation of empirical antifungal treatment.
METHODS: Prospective randomized controlled single-center unblinded study, performed in a mixed ICU. A total of 110 patients were randomly assigned to a strategy in which empirical antifungal treatment duration was determined by (1,3)-β-D-glucan, mannan, and anti-mannan serum assays, performed on day 0 and day 4; or to a routine care strategy, based on international guidelines, which recommend 14 days of treatment. In the biomarker group, early stop recommendation was determined using an algorithm based on the results of biomarkers. The primary outcome was the percentage of survivors discontinuing empirical antifungal treatment early, defined as a discontinuation strictly before day 7.
RESULTS: A total of 109 patients were analyzed (one patient withdraw consent). Empirical antifungal treatment was discontinued early in 29 out of 54 patients in the biomarker strategy group, compared with one patient out of 55 in the routine strategy group [54% vs 2%, p < 0.001, OR (95% CI) 62.6 (8.1-486)]. Total duration of antifungal treatment was significantly shorter in the biomarker strategy compared with routine strategy [median (IQR) 6 (4-13) vs 13 (12-14) days, p < 0.0001). No significant difference was found in the percentage of patients with subsequent proven invasive Candida infection, mechanical ventilation-free days, length of ICU stay, cost, and ICU mortality between the two study groups.
CONCLUSIONS: The use of a biomarker-based strategy increased the percentage of early discontinuation of empirical antifungal treatment among critically ill patients with suspected invasive Candida infection. These results confirm previous findings suggesting that early discontinuation of empirical antifungal treatment had no negative impact on outcome. However, further studies are needed to confirm the safety of this strategy. This trial was registered at ClinicalTrials.gov, NCT02154178.
参考来源
- Rouzé A, Loridant S, Poissy J, et al. Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial. Intensive Care Med. 2017. PMID: 28936678. doi:10.1007/s00134-017-4932-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。